Home Biosimilar Antibodies Neuronal Signaling Beta Amyloid Crenezumab (Anti-Amyloid Beta)
For research use only. Not for use in humans.

Crenezumab (Anti-Amyloid Beta)

Synonyms: MABT 5102A; RG 7412

Crenezumab (Anti-Amyloid Beta) is a fully humanized  immunoglobulin (Ig) G4 monoclonal antibody that targets amyloid beta (Abeta) with potential for use in Alzheimer's disease research. MW: 143.58 kD.

Crenezumab (Anti-Amyloid Beta)

Quality Control

Batch: A276401 Purity: 99% Protein concentration: 14.9mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Beta Amyloid Others
DAPT 404 Notch
RO4929097 (RG-4733) 126 γ secretase,Notch
Semagacestat (LY450139) 22 Notch
MK-0752 23
Avagacestat (BMS-708163) 22
LY2811376 19 BACE1
CRANAD-2 0
Hoechst 34580 2
Frentizole 0
Simufilam 1
Ginsenoside Rg1 7 NF-κB
Ginsenoside Re 2 NF-κB,JNK
Tabersonine hydrochloride 2
EUK 134 8
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Crenezumab (Anti-Amyloid Beta) is a fully humanized  immunoglobulin (Ig) G4 monoclonal antibody that targets amyloid beta (Abeta) with potential for use in Alzheimer's disease research. MW: 143.58 kD.
References

Product Details

CAS No. 1095207-05-8
Molecular Weight 143.58
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03977584 COMPLETED Drug: Crenezumab|Drug: Placebo Alzheimer Disease Hoffmann-La Roche 2019-06-10 PHASE2
NCT01998841 COMPLETED Drug: Crenezumab|Drug: Placebo Alzheimer's Disease Genentech, Inc. 2013-12-20 PHASE2
NCT03114657 TERMINATED Drug: Crenezumab|Drug: Placebo Alzheimer's Disease Hoffmann-La Roche 2017-03-29 PHASE3
NCT02670083 TERMINATED Drug: Crenezumab|Drug: Placebo Alzheimer's Disease Hoffmann-La Roche 2016-03-22 PHASE3
NCT03491150 TERMINATED Drug: Crenezumab Alzheimer's Disease Hoffmann-La Roche 2018-04-11 PHASE3
NCT01723826 COMPLETED Drug: Crenezumab Alzheimer's Disease Genentech, Inc. 2012-12-07 PHASE2

(data from https://clinicaltrials.gov, updated on 2024-03-15)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.